Matches in SemOpenAlex for { <https://semopenalex.org/work/W2461294485> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2461294485 endingPage "128" @default.
- W2461294485 startingPage "123" @default.
- W2461294485 abstract "Fully automated multiplex nucleic acid amplification technology ( NAT ) enabling individual‐donation ( ID ) or minipool of 6 ( MP 6) screening for HIV , HCV and HBV is provided by two major commercial players (Grifols/Hologic and Roche). In August 2014, Roche released the cobas MPX assay performed on the high‐throughput cobas 8800 and 6800 instruments. Grifols recently released their Ultrio Elite assay which includes detection of HIV ‐2 and is performed on the Panther platform and allows random access of sample and reagent loading during processing, which streamlines functionality and improves turnaround time. At the end of June 2015, 61 countries perform NAT to screen the blood supply. Of these, 16 and 18 countries screen entirely with NAT systems either from Roche or from Grifols, respectively, and the remaining 27 countries use a combination of both methods in their country. Twenty countries screen entirely using ID ‐ NAT and the remaining 41 countries use either MP or a combination of MP and ID ‐ NAT . The cobas MPX Roche assay has a 95% limit of detection ( LOD ) of 25·7 IU /ml ( CI 21·1–32·8), 7·0 IU /ml ( CI 5·9–8·6) and 1·4 IU /ml ( CI 1·2–1·7) for HIV ‐1, HCV and HBV , respectively. The Ultrio Elite Grifols assay has a LOD of 18 IU /ml (15–23·5), 3·0 IU /ml (2·5–3·9) and 4·3 IU /ml ( CI 3·8–5·0) for HIV , HCV and HBV , respectively. There have been 4 anecdotal cases of proven ID ‐ NAT breakthrough transmission cases of both window period ( WP ) and occult HBV infection ( OBI ) highlighting the importance of selective donor recruitment in addition to state‐of‐the‐art screening." @default.
- W2461294485 created "2016-07-22" @default.
- W2461294485 creator A5000374182 @default.
- W2461294485 creator A5077027924 @default.
- W2461294485 date "2016-06-01" @default.
- W2461294485 modified "2023-09-27" @default.
- W2461294485 title "The current status of nucleic acid amplification technology in transfusion-transmitted infectious disease testing" @default.
- W2461294485 cites W1571885045 @default.
- W2461294485 cites W1590606383 @default.
- W2461294485 cites W1628126137 @default.
- W2461294485 cites W1680972752 @default.
- W2461294485 cites W1841051061 @default.
- W2461294485 cites W1851982349 @default.
- W2461294485 cites W1859074717 @default.
- W2461294485 cites W1877071241 @default.
- W2461294485 cites W1905270355 @default.
- W2461294485 cites W1930057592 @default.
- W2461294485 cites W1935568567 @default.
- W2461294485 cites W1938433913 @default.
- W2461294485 cites W1977900740 @default.
- W2461294485 cites W1997341791 @default.
- W2461294485 cites W1999858864 @default.
- W2461294485 cites W2000150165 @default.
- W2461294485 cites W2002875155 @default.
- W2461294485 cites W2054307650 @default.
- W2461294485 cites W2054968660 @default.
- W2461294485 cites W2085605692 @default.
- W2461294485 cites W2101534707 @default.
- W2461294485 cites W2144671131 @default.
- W2461294485 cites W2145872391 @default.
- W2461294485 cites W2145893755 @default.
- W2461294485 cites W2153355234 @default.
- W2461294485 doi "https://doi.org/10.1111/voxs.12256" @default.
- W2461294485 hasPublicationYear "2016" @default.
- W2461294485 type Work @default.
- W2461294485 sameAs 2461294485 @default.
- W2461294485 citedByCount "5" @default.
- W2461294485 countsByYear W24612944852018 @default.
- W2461294485 countsByYear W24612944852019 @default.
- W2461294485 countsByYear W24612944852020 @default.
- W2461294485 countsByYear W24612944852022 @default.
- W2461294485 crossrefType "journal-article" @default.
- W2461294485 hasAuthorship W2461294485A5000374182 @default.
- W2461294485 hasAuthorship W2461294485A5077027924 @default.
- W2461294485 hasConcept C105795698 @default.
- W2461294485 hasConcept C142462285 @default.
- W2461294485 hasConcept C159047783 @default.
- W2461294485 hasConcept C182516595 @default.
- W2461294485 hasConcept C2781188995 @default.
- W2461294485 hasConcept C3013748606 @default.
- W2461294485 hasConcept C33923547 @default.
- W2461294485 hasConcept C60644358 @default.
- W2461294485 hasConcept C71924100 @default.
- W2461294485 hasConcept C86803240 @default.
- W2461294485 hasConceptScore W2461294485C105795698 @default.
- W2461294485 hasConceptScore W2461294485C142462285 @default.
- W2461294485 hasConceptScore W2461294485C159047783 @default.
- W2461294485 hasConceptScore W2461294485C182516595 @default.
- W2461294485 hasConceptScore W2461294485C2781188995 @default.
- W2461294485 hasConceptScore W2461294485C3013748606 @default.
- W2461294485 hasConceptScore W2461294485C33923547 @default.
- W2461294485 hasConceptScore W2461294485C60644358 @default.
- W2461294485 hasConceptScore W2461294485C71924100 @default.
- W2461294485 hasConceptScore W2461294485C86803240 @default.
- W2461294485 hasIssue "S2" @default.
- W2461294485 hasLocation W24612944851 @default.
- W2461294485 hasOpenAccess W2461294485 @default.
- W2461294485 hasPrimaryLocation W24612944851 @default.
- W2461294485 hasRelatedWork W1945359667 @default.
- W2461294485 hasRelatedWork W1973460911 @default.
- W2461294485 hasRelatedWork W2067655447 @default.
- W2461294485 hasRelatedWork W2069346294 @default.
- W2461294485 hasRelatedWork W2096903645 @default.
- W2461294485 hasRelatedWork W2140412799 @default.
- W2461294485 hasRelatedWork W2531059238 @default.
- W2461294485 hasRelatedWork W2751440690 @default.
- W2461294485 hasRelatedWork W39716245 @default.
- W2461294485 hasRelatedWork W4252053498 @default.
- W2461294485 hasVolume "11" @default.
- W2461294485 isParatext "false" @default.
- W2461294485 isRetracted "false" @default.
- W2461294485 magId "2461294485" @default.
- W2461294485 workType "article" @default.